YÜCE, T. H. Et Al. 2023. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.150, no.2 .

YÜCE, T. H., AK, G., METİNTAŞ, S., DÜNDAR, E., Roe, O. D., Panou, V., ... METİNTAŞ, M.(2023). BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.150, no.2.

YÜCE, TUNA Et Al. "BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.150, no.2, 2023

YÜCE, TUNA H. Et Al. "BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.150, no.2, 2023

YÜCE, T. H. Et Al. (2023) . "BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.150, no.2.

@article{article, author={TUNA HAN YÜCE Et Al. }, title={BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2023}